RU
FR
ES
HI
VI
EN
Advanced Meditech Center Specializing In
Early Detection And Treatment Of Fatal Diseases
Before Symptoms Appear In Diagnostics.
Take part in the expansion of global business that is the next generation approach to the Medical Science Industry.
MediTech Hub
Meditech is a platform designed to foster and fully support innovative advancements in contemporary health diagnostic systems
01
Advancing technology
Developing and evaluating diagnostic systems
02
Design
Formulating new diagnostic technologies
03
Certification
Securing global sales authorization
04
Introduce to the market
Products will be sequentially rolled out to the global market, enhancing the product range.
Our analysts diligently track advancements in medical technology, assess business performance, and analyze market dynamics. As a result, we present the most promising innovations currently available.
Key Objective
(RCBA) Robotic Cell Behavior Analyzer (For Commercial Purpose and Family Care) and (RCBAA) Robotic Cell Behavior Analyzer and Aligner (For Commercial Purpose)
Regularly monitoring of cell behavior indicates transformation of normal cell into Maligant cells in the premature stage. RCBAA helps in biologically aligning.
Separate device for commercial purpose and personal care will be developed.
Separate device for commercial purpose and personal care will be developed.
01
Detector with a detachable sensor
Transmitter with a module sensor for regular cell behavior pattern analyzer.
02
Application
Mobile App to track periodic cellular behavior
03
Action
If there is a disturbance, the RCBA alerts the user via mobile phone, enabling prompt response to prevent potential complications.
How Fatal
In 2022 20 Million cancer cases were recorded
Life Expectancy
Every next cancer patient is being killed; 10 million cancer related death recorded in 2022
Most Common Cancer
Out of 2.5 Million Lung Cancer patients 1.8 (72%) million didn’t survive.
Highly Prone
50 and above aged individuals are highly prone; however cancer can appear in any age.
Market Dynamics And Earnings Potential For The Industry
The global cancer treatment industry exceeds $80 billion in value and is experiencing rapid growth.
Currently, the availability of RCBAA treatments on the market is insufficient to meet the escalating global demand.
To lower costs and enhance health outcomes, it is essential to expand access to advanced cancer treatments.
$173 Billion
In 2022 Global profit of surgical equipments and medication over cancer world wide.
$267 Billion
Profit projected to reach $267 Billion by 2029 with a compounding growth of 6.3%
$208.9 Billion
In United States alone $208.9 Billion was estimated in 2020
Democratized investment options
Lifetime opportunity to become a co-owner of the project and buy investment shares in the company at the best possible price
$25 Billion
RCBA and RCBAA market assessment by 2028
